etoposide phosphate and Hodgkin Disease

etoposide phosphate has been researched along with Hodgkin Disease in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cirillo, M; O'Sullivan, M; Polistena, P; Purtill, D; Tran, Q	1
Briggs, A; Chow, HH; Dorr, RT; Kintzel, P; List, A; Meyers, R	1
Alscher, A; Casper, J; Decker, S; Freund, M; Junghanss, C; Kleine, HD; Knopp, A; Köhne, CH; Leithäuser, M; Wilhelm, S	1

Trials

1 trial(s) available for etoposide phosphate and Hodgkin Disease

Article	Year
Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation. Bone marrow transplantation, 2003, Volume: 31, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Etoposide; Hodgkin Disease; Humans; Life Expectancy; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Stem Cell Transplantation; Time Factors; Transplantation, Autologous	2003

Article

Year

Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.

Bone marrow transplantation, 2003, Volume: 31, Issue:8

Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Etoposide; Hodgkin Disease; Humans; Life Expectancy; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Stem Cell Transplantation; Time Factors; Transplantation, Autologous

2003

Other Studies

2 other study(ies) available for etoposide phosphate and Hodgkin Disease

Article	Year
Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma. Bone marrow transplantation, 2017, Volume: 52, Issue:3 Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Etoposide; Hodgkin Disease; Humans; Male; Organophosphorus Compounds; Recurrence	2017
High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize. Annals of hematology, 2001, Volume: 80, Issue:2 Topics: Adult; Choriocarcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organophosphorus Compounds; Therapeutic Equivalency; Transplantation Conditioning; Whole-Body Irradiation	2001

Article

Year

Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma.

Bone marrow transplantation, 2017, Volume: 52, Issue:3

Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Etoposide; Hodgkin Disease; Humans; Male; Organophosphorus Compounds; Recurrence

2017

High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize.

Annals of hematology, 2001, Volume: 80, Issue:2

Topics: Adult; Choriocarcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organophosphorus Compounds; Therapeutic Equivalency; Transplantation Conditioning; Whole-Body Irradiation

2001